non abstract related programme · title symposium precision medicine for metastatic breast cancer...
TRANSCRIPT
NON ABSTRACT RELATED PROGRAMME
Keynote lectures .......................................................................................................................... 2
Basic science ............................................................................................................................... 3
Breast cancer, early ..................................................................................................................... 5
Breast cancer, metastatic............................................................................................................. 7
CNS tumours ............................................................................................................................... 9
Developmental therapeutics ....................................................................................................... 11
Gastrointestinal tumours, colorectal ........................................................................................... 13
Gastrointestinal tumours, non-colorectal .................................................................................... 15
Genitourinary tumours, prostate ................................................................................................. 17
Genitourinary tumours, non-prostate ......................................................................................... 19
Gynaecological cancers ............................................................................................................. 21
Haematological malignancies .................................................................................................... 23
Head & neck cancer ................................................................................................................... 25
Immunotherapy of cancer .......................................................................................................... 27
Melanoma and other skin tumours ............................................................................................. 29
NETs and endocrine tumours .................................................................................................... 31
Non-metastatic NSCLC and other thoracic malignancies ......................................................... 33
NSCLC, metastatic .................................................................................................................... 35
Public health and health economics ........................................................................................... 37
Sarcoma ..................................................................................................................................... 39
Supportive and palliative care .................................................................................................... 41
Translational research................................................................................................................ 43
Congress highlights ................................................................................................................... 45
Joint Symposia ........................................................................................................................... 46
ESMO Clinical Practice Guidelines ............................................................................................ 55
Special sessions ........................................................................................................................ 56
Young oncologists ...................................................................................................................... 63
PAWG ........................................................................................................................................ 68
Keynote lectures Saturday, 9 September 2017, 08:15-09:00 45 mins
Final Title Clinical implications of tumour evolution
Chair Alberto Bardelli, IT
Speaker Charlie Swanton, UK
Sunday, 10 September 2017, 08:15-09:00 45 mins
Final Title Coping with escalating healthcare costs in 2017 and beyond (Issue of ratio between cost and price of new agents)
Chair Paolo Casali, IT
Speaker Josep Tabernero, ES
Monday, 11 September 2017, 08:15-09:00 45 mins
Final Title Does immunotherapy cure advanced cancer?
Chair Inge Marie Svane
Speaker John Haanen, NL
Basic science
Challenge your Expert Saturday, 9 September 2017, 08:00-09:00 45 mins
Final Title Progress in pancreatic cancer
Chair Anton Berns, NL
Speaker David Tuveson, US
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Monday, 11 September 2017, 11:00-12:30 90 mins
Title Treating your patients using epigenetics
Chair Kristian Helin, DK
Co-Chair David Huntsman, CA
Title presentation 1 Targeting epigenetic enzymes in cancer
Speaker 1 Kristian Helin, DK
Lecture time 25’
Title presentation 2 Deacetylation of chromatin: a new target for epigenetic therapy?
Speaker 2 Nicholas La Thangue, UK
Lecture time 25’
Title presentation 3 Protein Methyltransferase inhibitors in preclinical models and clinical studies
Speaker 3 Caretha L. Creasy, US
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Friday, 8 September 2017, 16:00-17:30 90 mins
Title symposium Cancer stem cell properties
Chair Andreas Trumpp, DE
Co-Chair Anton Berns, NL
Title presentation 1 Introduction
Speaker 1 Andreas Trumpp, DE
Lecture time 1 5’
Title presentation 2 Stem cell re-programming in cancer tissues
Speaker 2 Axel Behrens, UK
Lecture/disc time 2 20’
Title presentation 3 Clonal tracking of stem cells
Speaker 3 John Dick, CA
Lecture/disc time 3 20’
Title presentation 4 Stem and progenitor cells in epithelial cancer
Speaker 4 Rune Toftgård, SE
Lecture/disc time 4 20’
Title presentation 5 Normal and malignant stem cells
Speaker 5 Andreas Trumpp, DE
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Anton Berns, NL
Lecture/disc time 6 5’
Special session Monday, 11 September 2017, 09:30-10:30 60 mins
Topic Overcoming drug resistance
Chair Ultan McDermott, UK
Co-Chair Richard Marais, UK
Title presentation 1 Genome-wide genetic screens: Defining and overcoming the drug resistance landscape
Speaker 1 Ultan McDermott, UK
Title presentation 2 Cancer evolution as a therapeutic target
Speaker 2 Alberto Bardelli, IT
Title presentation 3 Predictive markers for ovarian carcinoma
Speaker 3 David Huntsman, CA
Lecture/disc time Each speaker c. 20’
Breast cancer, early
Challenge your Expert Sunday, 10 September 2017, 08:00-09:00 45 mins
Final Title Locoregional challenges with neoadjuvant systemic therapy (surgery and radiation)
Chair Elzbieta Senkus, PL
Speaker Michael Gnant, AT
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Saturday, 9 September 2017, 09:00-10:30 90 mins
Title Controversial issues in the neoadjuvant approach to early breast cancer
Chair Javier Cortes, ES
Co-Chair Nadia Harbeck, DE
Title presentation 1 Luminal
Speaker 1 Christoph Thomssen, DE
Lecture time 25’
Title presentation 2 Triple negative breast cancer (TNBC)
Speaker 2 Andrew Tutt, UK
Lecture time 25’
Title presentation 3 HER2
Speaker 3 Javier Cortes, ES
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Sunday, 10 September 2017, 11:00-12:40 100 mins
Title symposium How to manage luminal breast cancer
Chair Fatima Cardoso, PT
Co-Chair Marco Colleoni, IT
Title presentation 1 How to classify luminal breast cancer
Speaker 1 Jorge Reis-Filho, US
Lecture time 1 20’
Title presentation 3 Who benefits from chemotherapy?
Speaker 3 Fatima Cardoso, PT
Lecture/disc time 3 20’
Title presentation 4 Early response assessment
Speaker 4 Nadia Harbeck, DE
Lecture/disc time 4 20’
Title presentation 5 How much endocrine therapy is long enough?
Speaker 5 Marco Colleoni, IT
Lecture/disc time 5 20’
Title presentation 2 Is there an optimal chemotherapy?
Speaker 2 Angelo Di Leo, IT
Lecture/disc time 2 20’
Multidisciplinary Session Monday, 11 September 2017, 09:30-10:30 60 mins
Title Treatment of young women with breast cancer
Chair Olivia Pagani, CH
Panel Suzette Delaloge, FR and Fedro Peccatori, IT
Title presentation 1 Presentation of case/condition and
Issues on systemic treatment
Speaker 1 Olivia Pagani, CH
Title presentation 2 Issues on genetics
Speaker 2 Suzette Delaloge, FR
Title presentation 3 Issues on fertility
Speaker 3 Fedro Peccatori, IT
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Breast cancer, metastatic
Challenge your Expert Monday, 11 September 2017, 08:00-09:00 45 mins
Final Title Is it necessary to operate oligometastatic disease?
Chair Roman Rouzier, FR
Speaker Fatima Cardoso, PT
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Saturday, 9 September 2017, 16:30-18:00 90 mins
Title CDK4 inhibitors in metastatic breast cancer
Chair Sibylle Loibl, DE
Co-Chair Sherene Loi, AU
Title presentation 1 Rationale to target CDK4
Speaker 1 Ben O’Leary, UK
Lecture time 25’
Title presentation 2 Efficacy of CDK4 inhibitors: Data from clinical trials
Speaker 2 Sibylle Loibl, DE
Lecture time 25’
Title presentation 3 Triple combination with PI3K
Speaker 3 Dejan Juric, US
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Monday, 11 September 2017, 16:30-18:00 90 mins
Title Update on new therapies for triple negative breast cancer (TNBC)
Chair Peter Schmid, UK
Co-Chair Frederique Penault-Llorca, FR
Title presentation 1 PARP inhibitors
Speaker 1 Judy Garber, US
Lecture time 25’
Title presentation 2 Immunotherapeutics
Speaker 2 Peter Schmid, UK Lecture time 25’
Title presentation 3 Androgen receptor
Speaker 3 Hervé Bonnefoi, FR
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Sunday, 10 September 2017, 14:45-16:15 90 mins
Title symposium Precision medicine for metastatic breast cancer
Chair Christos Sotiriou, BE
Co-Chair Thomas Bachelot, FR
Title presentation 1 The genomic landscape of metastatic breast cancer
Speaker 1 Lucy Yates, UK
Lecture time 1 20’
Title presentation 2 Targeting PI3K
Speaker 2 Sherene Loi, AU
Lecture/disc time 2 20’
Title presentation 3 Clinical utility of large panel of genes
Speaker 3 Monica Arnedos, FR
Lecture/disc time 3 20’
Title presentation 4 Clinical utility of circulating DNA
Speaker 4 Nick Turner, UK
Lecture/disc time 4 20’
Title presentation 5 Clinical perspectives: Which genomic tests should be used in mBC?
Speaker 5 Christos Sotiriou, BE
Lecture/disc time 5 10’
Multidisciplinary Session Monday, 11 September 2017, 15:00-16:00 60 mins
Title Management of brain metastases
Chair Thomas Bachelot, FR
Panel Colin Watts, UK and Frederic Dhermain, FR
Title presentation 1 Presentation of case/condition and
The medical oncology perspective
Speaker 1 Thomas Bachelot, FR
Title presentation 2 The radiation therapy perspective
Speaker 2 Frederic Dhermain, FR
Title presentation 3 The neurosurgery perspective
Speaker 3 Colin Watts, UK
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
CNS tumours
Challenge your Expert Saturday, 9 September 2017, 08:00-09:00 45 mins
Final Title How to use molecular biology in neuro-oncology
Chair Michael Weller, CH
Speaker Martin van den Bent, NL
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Friday, 8 September 2017, 14:00-15:30 90 mins
Title Standard of diagnosis and care in brain tumours
Chair Patrick Wen, US
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 The new WHO classification
Speaker 1 Guido Reifenberger, DE
Lecture time 25’
Title presentation 2 How do I use the Response Assessment in Neuro-Oncology (RANO) criteria?
Speaker 2 Patrick Wen, US
Lecture time 25’
Title presentation 3 How to manage complications of radiotherapy and chemotherapy?
Speaker 3 Speaker TBC
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Sunday, 10 September 2017, 11:00-12:30 90 mins
Title symposium Targeted therapy in neuro-oncology
Chair Patrick Wen, US
Co-Chair Pim French, NL
Title presentation 1 Introduction
Speaker 1 Pim French, NL
Lecture time 1 5’
Title presentation 2 What can we learn from patient-derived models?
Speaker 2 Joan Seoane, ES
Lecture/disc time 2 20’
Title presentation 3 Is IDH a valid therapeutic target in neuro-oncology?
Speaker 3 Michael Platten, DE
Lecture/disc time 3 20’
Title presentation 4 Targeting EGFR in glioblastoma: Beyond TKI and ACT IV
Speaker 4 Michael Weller, CH
Lecture/disc time 4 20’
Title presentation 5 Basket & umbrella trials in neuro-oncology
Speaker 5 Wolfgang Wick, DE
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Patrick Wen, US
Lecture/disc time 6 5’
Multidisciplinary Session Saturday, 9 September 2017, 11:00-12:00 60 mins
Title Diagnosis and management of leptomeningeal metastasis
Chair Emilie Le Rhun, FR
Panel Jörg Tonn, DE and Salvador Villa, ES
Title presentation 1 Presentation of case/condition and
Systemic versus intrathecal chemotherapy
Speaker 1 Emilie Le Rhun, FR
Title presentation 2 Is there a role for surgery?
Speaker 2 Jörg Tonn, DE
Title presentation 3 Treatment concepts in radiation oncology
Speaker 3 Salvador Villà, ES
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Developmental therapeutics
Challenge your Expert Monday, 11 September 2017, 09:30-10:30 60 mins
Final Title Integration of molecular imaging into drug development
Chair Udai Banerji, UK
Speaker Elisabeth de Vries, NL
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Sunday, 10 September 2017, 09:15-10:45 90 mins
Title Immunotherapy beyond checkpoint inhibitors
Chair Marcela Maus, US
Co-Chair Ruth Plummer, UK
Title presentation 1 Biomarkers for personalised immunotherapy
Speaker 1 Aurelien Marabelle, FR
Lecture time 25’
Title presentation 2 Modulation of tumour microenvironments
Speaker 2 Leila Akkari, NL
Lecture time 25’
Title presentation 3 CAR-T and beyond
Speaker 3 Marcela Maus, US
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Monday, 11 September 2017, 14:45-16:15 90 mins
Title symposium Emerging topics in developmental therapeutics
Chair Anthony Chalmers, UK
Co-Chair Ulrik Lassen, DK
Title presentation 1 Introduction
Speaker 1 Ulrik Lassen, DK
Lecture time 1 5’
Title presentation 2 DNA and RNA basic strategies in early drug development
Speaker 2 René Bernards, NL
Lecture/disc time 2 15’
Title presentation 3 Combined modality of radiation DDR
Speaker 3 Anthony Chalmers, UK
Lecture/disc time 3 15’
Title presentation 4 Targeting metabolism
Speaker 4 Eyal Gottlieb, UK
Lecture/disc time 4 15’
Title presentation 5 Developmental therapeutics in rare tumours
Speaker 5 Nathalie Gaspar, FR
Lecture/disc time 5 15’
Title presentation 6 Targeting the P53 pathway
Speaker 6 Lucilia Saraiva, PT
Lecture/disc time 6 15’
Title presentation 7 Conclusions and clinical perspectives
Speaker 7 Chair
Lecture/disc time 7 10’
Multidisciplinary Session Saturday, 9 September 2017, 15:00-16:00 60 mins
Title Management of toxicities
Chair Sophie Cousin, FR
Panel Tamar Nijsten, NL and Ursula Urner Bloch, CH
Title presentation 1 Presentation of Melanoma case and
The clinical oncology perspective
Speaker 1 Sophie Cousin, FR 10’
Title presentation 2 The dermatology perspective
Speaker 2 Tamar Nijsten, NL 5’
Title presentation 3 The ophthalmology perspective
Speaker 3 Ursula Urner Bloch, CH 5’
Title presentation 4 Presentation of TKI resistance case and
The clinical oncology perspective
Speaker 4 Sophie Cousin, FR 10’
Title presentation 5 The dermatology perspective
Speaker 5 Tamar Nijsten, NL 5’
Title presentation 6 The ophthalmology perspective
Speaker 6 Ursula Urner Bloch, CH 5’
Lecture time 10’ discussion after each of the 2 cases 20’
Gastrointestinal tumours, colorectal
Challenge your Expert Monday, 11 September 2017, 08:00-09:00 45 mins
Final Title Liver dominant disease (incl. surgical treatment, radiofrequency ablation and radiotherapy)
Chair Gunnar Folprecht, DE
Speaker René Adam, FR
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Friday, 8 September 2017, 14:00-15:30 90 mins
Title Optimal therapy in localised rectal cancer
Chair Andrés Cervantes, ES
Co-Chair Julien Taieb, FR
Title presentation 1 Imaging and re-imaging
Speaker 1 Regina Beets-Tan, NL
Lecture time 25’
Title presentation 2 What treatment should be skipped or intensified?
Speaker 2 Bengt Glimelius, SE Lecture time 25’
Title presentation 3 Adjuvant therapy
Speaker 3 Andrés Cervantes, ES
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Saturday, 9 September 2017, 14:45-16:15 90 mins
Title Molecular targeted therapy of advanced colorectal cancer
Chair Gary Middleton, UK
Co-Chair Rob Glynne-Jones, UK
Title presentation 1 BRAF mutant patients (incl. heterogeneity)
Speaker 1 Michel Ducreux, FR
Lecture time 25’
Title presentation 2 MSI
Speaker 2 Gary Middleton, UK Lecture time 25’
Title presentation 3 Rare mutations (Incl HER2 and others)
Speaker 3 Livio Trusolino, IT
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Sunday, 10 September 2017, 09:15-10:45 90 mins
Title symposium Optimal treatment of RAS mutated patients
Chair Volker Heinemann, DE
Co-Chair Alfredo Falcone, IT
Title presentation 1 Introduction
Speaker 1 Alfredo Falcone, IT
Lecture time 1 5’
Title presentation 2 Liquid biopsies
Speaker 2 Marc Ychou, FR
Lecture/disc time 2 20’
Title presentation 3 Molecular heterogeneity
Speaker 3 Fortunato Ciardiello, IT
Lecture/disc time 3 20’
Title presentation 4 New ways of targeting RAS
Speaker 4 Ryan Corcoran, US
Lecture/disc time 4 20’
Title presentation 5 Immunotherapy: MSI and beyond
Speaker 5 Johanna Bendell, US
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Volker Heinemann, DE
Lecture/disc time 6 5’
Multidisciplinary Session Monday, 11 September 2017, 11:00-12:00 60 mins
Title Synchronous liver metastases in rectal cancer: Which treatment first?
Chair Rob Glynne-Jones, UK
Panel Thomas Gruenberger, AT and Per Pfeiffer, DK
Title presentation 1 Presentation of case/condition and
The radiation therapy perspective
Speaker 1 Rob Glynne-Jones, UK
Title presentation 2 The surgical oncology perspective
Speaker 2 Thomas Gruenberger, AT
Title presentation 3 The medical oncology perspective
Speaker 3 Per Pfeiffer, DK
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Gastrointestinal tumours, non-colorectal
Challenge your Expert Sunday, 10 September 2017, 08:00-09:00 45 mins
Final Title GE junction tumours
Chair Hanneke van Laarhoven, NL
Speaker David Cunningham, UK
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Saturday, 9 September 2017, 16:30-18:00 90 mins
Title Pancreatic cancer
Chair Eric Van Cutsem, BE
Co-Chair Thomas Seufferlein, DE
Title presentation 1 New approaches in genetic classification and translational studies
Speaker 1 Giampaolo Tortora, IT
Lecture time 25’
Title presentation 2 Neoadjuvant vs adjuvant
Speaker 2 Thomas Seufferlein, DE
Lecture time 25’
Title presentation 3 New treatment combinations in metastatic disease
Speaker 3 Eileen O’Reilly, US
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Saturday, 9 September 2017, 11:00-12:30 90 mins
Title symposium Immuno-oncology in upper GI cancer: PD1 and beyond
Chair Sergio Quezada, UK
Co-Chair Florian Lordick, DE
Title presentation 1 Introduction
Speaker 1 Florian Lordick, DE
Lecture time 1 5’
Title presentation 2 Relationship between microbiota and immunotherapy
Speaker 2 Laurence Zitvogel, FR
Lecture/disc time 2 20’
Title presentation 3 The role of the environment and stroma
Speaker 3 Sunil R. Hingorani, US
Lecture/disc time 3 20’
Title presentation 4 Biomarkers to predict the effects of immunotherapy
Speaker 4 Sergio Quezada, UK
Lecture/disc time 4 20’
Title presentation 5 Overview of clinical activity of immunomodulating agents in upper GI cancer
Speaker 5 Christophe Borg, FR
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Sergio Quezada, UK
Lecture/disc time 6 5’
Multidisciplinary Session Sunday, 10 September 2017, 15:00-16:00 60 mins
Title Management of locally advanced gastric and oesophageal
adenocarcinoma
Chair Florian Lordick, DE
Panel Trevor Leong, AU and Christophe Mariette, FR
Title presentation 1 Presentation of case/condition and
The medical oncology perspective
Speaker 1 Florian Lordick, DE
Title presentation 2 The radiation therapy perspective
Speaker 2 Trevor Leong, AU
Title presentation 3 The surgery perspective
Speaker 3 Christophe Mariette, FR
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Genitourinary tumours, prostate
Challenge your Expert Saturday, 9 September 2017, 08:00-09:00 45 mins
Final Title Germline aberrations and prostate cancer
Chair Ros Eeles, UK
Speaker Elena Castro, ES
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Sunday, 10 September 2017, 11:00-12:30 90 mins
Title Optimising treatment of metastatic prostate cancer
Chair Nick James, UK
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Why switch treatment? Response biomarkers
Speaker 1 Howard Scher, US
Lecture time 25’
Title presentation 2 When to treat? How do we define best sequence?
Speaker 2 Nick James, UK
Lecture time 25’
Title presentation 3 Who to treat? Molecular stratification predictive biomarkers
Speaker 3 Joaquin Mateo, ES
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Monday, 11 September 2017, 09:15-10:45 90 mins
Title symposium Immunobiology in prostate cancer
Chair Himisha Beltran, US
Co-Chair Andrea Alimonti, CH
Title presentation 1 Introduction
Speaker 1 Himisha Beltran, US
Lecture time 1 5’
Title presentation 2 Basic immunobiology in prostate cancer
Speaker 2 Andrea Alimonti, CH
Lecture/disc time 2 20’
Title presentation 3 Immunogenomics and prostate cancer
Speaker 3 Johann de Bono, UK
Lecture/disc time 3 20’
Title presentation 4 Vaccination in prostate cancer
Speaker 4 James Gulley, US
Lecture/disc time 4 20’
Title presentation 5 Checkpoint inhibitors in prostate cancer
Speaker 5 Winald Gerritsen, NL
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Himisha Beltran, US
Lecture/disc time 6 5’
Multidisciplinary Interactive Session Monday, 11 September 2017, 15:00-16:00 60 mins
Title Management of M0 patient with rising PSA
Chair Karim Fizazi, FR
Panel Uwe Haberkorn, DE and Nina Tunariu, UK
Title presentation 1 Presentation of case/condition -
The clinical problem: A multi-disciplinary issue
Speaker 1 Karim Fizazi, FR
Title presentation 2 How can PET imaging help?
Speaker 2 Uwe Haberkorn, DE
Title presentation 3 How can MRI imaging help?
Speaker 3 Nina Tunariu, UK
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Genitourinary tumours, non-prostate
Challenge your Expert Sunday, 10 September 2017, 08:00-09:00 45 mins
Final Title Multidisciplinary management of localised high risk bladder cancer
Chair Aris Bamias, GR
Speaker Andrea Necchi, IT
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Friday, 8 September 2017, 16:00-17:30 90 mins
Title What is new in germ cell tumours
Chair Antonio Lopez Beltran, ES
Co-Chair Aris Bamias, GR
Title presentation 1 What is new in the biology of germ cell tumours
Speaker 1 Antonio Lopez Beltran, ES
Lecture time 25’
Title presentation 2 Refining prognosis assessment in germ cell tumours
Speaker 2 Jan Oldenburg, NO
Lecture time 25’
Title presentation 3 The role of high dose chemotherapy in refractory resistant germ cell tumours
Speaker 3 Joerg Beyer, CH
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Monday, 11 September 2017, 11:00-12:30 90 mins
Title symposium Impact of tumour heterogeneity on precision medicine in kidney and bladder cancers
Chair Laurence Albiges, FR
Co-Chair Camillo Porta, IT
Title presentation 1 Introduction
Speaker 1 Camillo Porta, IT
Lecture time 1 5’
Title presentation 2 What is the current status of precision medicine
Speaker 2 Christophe Massard, FR
Lecture/disc time 2 20’
Title presentation 3 The impact of tumour heterogeneity on precision medicine
Speaker 3 Marco Gerlinger, UK
Lecture/disc time 3 20’
Title presentation 4 Is genomic classification going to help in RCC?
Speaker 4 Laurence Albiges, FR
Lecture/disc time 4 20’
Title presentation 5 Is genomic classification going to help in bladder cancer?
Speaker 5 Joaquim Bellmunt, US
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Laurence Albiges, FR
Lecture/disc time 6 5’
Multidisciplinary Session Saturday, 9 September 2017, 11:00-12:00 60 mins
Title Lymph involvement in GU cancer
Chair Petri Bono, FI
Panel Vincent Khoo, UK and Axel Bex, NL
Title presentation 1 Presentation of case/condition and
The medical oncology perspective
Speaker 1 Petri Bono, FI
Title presentation 2 The radiation therapy perspective
Speaker 2 Vincent Khoo, UK
Title presentation 3 The surgery perspective
Speaker 3 Axel Bex, NL
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Gynaecological cancers
Challenge your Expert Sunday, 10 September 2017, 09:30-10:30 45 mins
Final Title Personalised and stratified management of non-epithelial ovarian cancer
Chair Isabelle Ray-Coquard, FR
Speaker Jonathan Ledermann, UK
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Saturday, 9 September 2017, 14:45-16:15 90 mins
Title How to manage ovarian cancer in 2017
Chair Sandro Pignata, IT
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Biological implications for clinical practice
Speaker 1 Sandro Pignata, IT
Lecture time 20’
Title presentation 2 Front line surgery: Criteria for selection
Speaker 2 Philipp Harter, DE
Lecture time 20’
Title presentation 3 Medical management of recurrent disease
Speaker 3 Antonio González-Martín, ES
Lecture time 20’
Title presentation 4 Is there a role for surgical management of recurrent disease?
Speaker 4 Ignace Vergote, BE
Lecture time 20’
Title presentation 5 Discussion
Lecture time 10’
Special symposium Sunday, 10 September 2017, 14:45-16:15 90 mins
Title symposium Immunotherapy and targeted therapies in gynaecological malignancies
Chair Susana Banerjee, UK
Co-Chair Jos Jonkers, NL
Title presentation 1 Introduction
Speaker 1 Susana Banerjee, UK
Lecture time 1 5’
Title presentation 2 Immunology of gynaecological tumours
Speaker 2 George Coukos, CH
Lecture/disc time 2 20’
Title presentation 3 Immunotherapy in gynaecological malignancies
Speaker 3 Eric Pujade-Lauraine, FR
Lecture/disc time 3 20’
Title presentation 4 Clinical implications of HRD beyond BRCA
Speaker 4 Jos Jonkers, NL
Lecture/disc time 4 20’
Title presentation 5 How to integrate PARP inhibitors into clinical practice
Speaker 5 Susana Banerjee, UK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Jos Jonkers, NL
Lecture/disc time 6 5’
Multidisciplinary Session Monday, 11 September 2017, 11:00-12:00 60 mins
Title Management of high risk early stage endometrial cancer
Chair Mansoor Mirza, DK
Panel Pierluigi Benedetti Panici, IT and Remy Nout, NL
Title presentation 1 Presentation of case/condition and
The medical oncology perspective
Speaker 1 Mansoor Mirza, DK
Title presentation 2 The surgery perspective
Speaker 2 Pierluigi Benedetti Panici, IT
Title presentation 3 The radiation therapy perspective
Speaker 3 Remy Nout, NL
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Haematological malignancies
Challenge your Expert Sunday, 10 September 2017, 08:00-09:00 45 mins
Final Title Secondary MDS and AML
Chair Javier De la Serna, ES
Speaker Mike Dennis, UK
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Monday, 11 September 2017, 09:15-10:45 90 mins
Title B cell receptor as a therapeutic target
Chair Andrés Ferreri, IT
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Diagnosis and classification of the pathologic subtypes of large B cell lymphoma: Immunophenotyping, gene expression profiling and mutational analyses
Speaker 1 Santiago Montes, ES
Lecture time 25’
Title presentation 2 Current therapies against B cell receptor
Speaker 2 Andrés Ferreri, IT
Lecture time 25’
Title presentation 3 Overcoming resistance in B cell receptor therapeutics
Speaker 3 Simon Rule, UK
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Saturday, 9 September 2017, 11:00-12:30 90 mins
Title symposium Immunotherapy and targeted therapies in lymphomas
Chair Mariano Provencio, ES
Co-Chair Andrés Ferreri, IT
Title presentation 1 Introduction
Speaker 1 Andrés Ferreri, IT
Lecture time 1 5’
Title presentation 2 Immune checkpoint inhibition
Speaker 2 Toby A. Eyre, UK
Lecture/disc time 2 20’
Title presentation 3 Antibody-drug complexes
Speaker 3 Speaker TBC
Lecture/disc time 3 20’
Title presentation 4 Bispecific T-cell engager
Speaker 4 Andreas Viardot, DE
Lecture/disc time 4 20’
Title presentation 5 CAR-T
Speaker 5 Gunilla Enblad, SE
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Mariano Provencio, ES
Lecture/disc time 6 5’
Multidisciplinary Session Sunday, 10 September 2017, 09:30-10:30 60 mins
Title Challenges and opportunities in the treatment of Hodgkin's lymphoma
Chair Umberto Ricardi, IT
Panel Sally Barrington, UK and Antonio Rueda Domínguez, ES
Title presentation 1 Presentation of case/condition and
The radiation therapy perspective
Speaker 1 Umberto Ricardi, IT
Title presentation 2 The nuclear medicine perspective
Speaker 2 Sally Barrington, UK
Title presentation 3 The medical oncology perspective
Speaker 3 Antonio Rueda Domínguez, ES
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Head & neck cancer
Challenge your Expert Monday, 11 September 2017, 08:00-09:00 45 mins
Final Title Management of elderly patients with head and neck cancer
Chair Joel stros, FR
Speaker Hans Langendijk, NL
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Sunday, 10 September 2017, 14:45-16:15 90 mins
Title Immunotherapy in head and neck cancer
Chair Amanda Psyrri, GR
Co-Chair Joel Guigay, FR
Title presentation 1 State of the art of immunotherapy in head and neck cancer
Speaker 1 Speaker TBC
Lecture time 25’
Title presentation 2 How to target immuno escape after anti PD-1
Speaker 2 Bob Ferris, US
Lecture time 25’
Title presentation 3 Rationale to combine with classical or novel therapies
Speaker 3 Amanda Psyrri, GR
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Sunday, 10 September 2017, 09:15-10:45 90 mins
Title symposium Innovative therapies in head and neck cancer
Chair Jean-Pascal Machiels, BE
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Introduction
Speaker 1 Jean-Pascal Machiels, BE
Lecture time 1 5’
Title presentation 2 Sense and non-sense of TransOral Robotic Surgery (TORS)
Speaker 2 Philippe Ceruse, FR
Lecture/disc time 2 20’
Title presentation 3 Proton therapy
Speaker 3 Damien Weber, CH
Lecture/disc time 3 20’
Title presentation 4 Precision medicine in head and neck cancer: Myth or reality?
Speaker 4 Lillian Siu, CA
Lecture/disc time 4 20’
Title presentation 5 Window of opportunity in clinical trials for biomarker discovery in head and neck cancer
Speaker 5 Christophe Le Tourneau, FR
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Co-Chair
Lecture/disc time 6 5’
Multidisciplinary Session Monday, 11 September 2017, 16:30-17:30 60 mins
Title Clinical challenges in head and neck cancer
Chair Marco Merlano, IT
Panel Vincent Grégoire, BE and Christian Simon, CH
Title presentation 1 Presentation of case/condition and
The medical oncology perspective
Speaker 1 Marco Merlano, IT
Title presentation 2 The radiation therapy perspective
Speaker 2 Vincent Grégoire, BE
Title presentation 3 The surgery perspective
Speaker 3 Christian Simon, CH
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Immunotherapy of cancer
Challenge your Expert Sunday, 10 September 2017, 08:00-09:00 45 mins
Final Title Management of patients on immunotherapy
Chair Inge Marie Svane, DK
Speaker Paul Lorigan, UK
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Friday, 8 September 2017, 14:00-15:30 90 mins
Title Immunotherapy: The next steps
Chair James Larkin, UK
Co-Chair Paul Nathan, UK
Title presentation 1 Combination of drugs acting on the immune system
Speaker 1 Suzanne Topalian, US
Lecture time 25’
Title presentation 2 How to sequence immunotherapy
Speaker 2 James Larkin, UK
Lecture time 25’
Title presentation 3 When to discontinue immunotherapy
Speaker 3 Caroline Robert, FR
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Saturday, 9 September 2017, 09:15-10:45 90 mins
Title symposium Predictive biomarkers for response to immunotherapy
Chair Daniel Speiser, CH
Co-Chair Fiona Thistlethwaite, UK
Title presentation 1 Introduction
Speaker 1 Fiona Thistlethwaite, UK
Lecture time 1 5’
Title presentation 2 New biomarkers for response to immunotherapy
Speaker 2 Christian Blank, NL
Lecture/disc time 2 20’
Title presentation 3 Biomarkers from biological basis to clinical relevance
Speaker 3 Daniel Speiser, CH
Lecture/disc time 3 20’
Title presentation 5 Can microbiota be a biomarker for immunotherapy?
Speaker 5 Laurence Zitvogel, FR
Lecture/disc time 5 20’
Title presentation 6 Tumour microenvironment: The role of the innate cell
Speaker 6 Mario Colombo, IT
Lecture/disc time 6 20’
Title presentation 7 Conclusions and clinical perspectives
Speaker 7 Daniel Speiser, CH
Lecture/disc time 7 5’
Special Session – instead of MS Sunday, 10 September 2017, 09:30-10:30 60 mins
Title Oligometastatic disease: Immunotherapy and /or local treatment
Chair Bart Neyns, BE
Title presentation 1 Is immunotherapy first choice?
Speaker 1 Bart Neyns, BE
Lecture time 10’
Title presentation 2 Radiotherapy is it the treatment and/or the adjuvant?
Speaker 2 Paul Nathan, UK
Lecture time 10’
Title presentation 3 Does surgery still have a role?
Speaker 3 Alexander van Akkooi, NL
Lecture time 10’
Title presentation 4 Discussion
Lecture time 30’
Melanoma and other skin tumours
Challenge your Expert Monday, 11 September 2017, 08:00-09:00 45 mins
Final Title Gut microbiota: Will it help to improve immunotherapy in melanoma?
Chair Caroline Robert, FR
Speaker Thomas Gajewski, US
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Sunday, 10 September 2017, 16:30-18:00 90 mins
Title State of the art of melanoma therapy
Chair Dirk Schadendorf, DE
Co-Chair Reinhard Dummer, CH
Title presentation 1 Is there still a role for surgery?
Speaker 1 Alessandro Testori, IT
Lecture time 20’
Title presentation 2 Adjuvant therapy: Still a role for interferon?
Speaker 2 Lex Eggermont, FR
Lecture time 20’
Title presentation 3 Targeted therapy: Still a role in 1st line?
Speaker 3 Dirk Schadendorf, DE
Lecture time 20’
Title presentation 4 Immunotherapy: still a role for ipilimumab?
Speaker 4 Olivier Michielin, CH
Lecture time 20’
Title presentation 5 Discussion
Lecture time 10’
Special symposium Saturday, 9 September 2017, 11:00-12:30 90 mins
Title symposium Mechanisms of intrinsic and acquired resistance to current treatment strategies
Chair Daniel Peeper, NL
Co-Chair Richard Marais, UK
Title presentation 1 Introduction
Speaker 1 Daniel Peeper, NL
Lecture time 1 5’
Title presentation 2 Intrinsic in immuno
Speaker 2 Grant McArthur, AU
Lecture/disc time 2 20’
Title presentation 3 Intrinsic in targeted
Speaker 3 Richard Marais, UK
Lecture/disc time 3 20’
Title presentation 4 Acquired in immuno
Speaker 4 Antoni Ribas, US
Lecture/disc time 4 20’
Title presentation 5 Acquired in targeted
Speaker 5 Daniel Peeper, NL
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Richard Marais, UK
Lecture/disc time 6 5’
Multidisciplinary Session Sunday, 10 September 2017, 15:00-16:00 60 mins
Title Treating patients with melanoma brain metastases
Chair Matthias Guckenberger, CH
Title presentation 1 Patient with BRAF mutation under kinase inhibitor therapy and controlled systemic disease developing 3 asymptomatic 1-2cm large brain metastases
Speaker 1 Paolo Ascierto, IT
Lecture time 10’
Title presentation 2 Patient under treatment with immunotherapy developing one single 2.5cm large symptomatic brain metastasis
Speaker 2 Matthias Guckenberger, CH
Lecture time 10’
Title presentation 3 Primary diagnosis of malignant melanoma with 7 symptomatic brain without other visceral metastases
Speaker 3 Reinhard Dummer, CH
Lecture time 10’
Title presentation 4 Discussion
Lecture time 30’
NETs and endocrine tumours
Challenge your Expert Monday, 11 September 2017, 09:30-10:30 45 mins
Final Title Management of typical and atypical lung neuroendocrine tumours
Chair Marianne Pavel, DE
Speaker Martyn Caplin, UK
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Monday, 11 September 2017, 16:30-18:00 90 mins
Title Neuroendocrine neoplasms of the gastroenteropancreatic system: From the bench to the bed
Chair Juan Valle, UK
Co-Chair Ian Chau, UK
Title presentation 1 Pathological characterisation of gastroenteropancreatic neuroendocrine neoplasms: Present and future
Speaker 1 Anne Couvelard, FR
Lecture time 25’
Title presentation 2 Present and future of nuclear medicine approach in neuroendocrine tumour management: From diagnosis to treatment
Speaker 2 Lisa Bodei, US
Lecture time 25’
Title presentation 3 Evidence-based decisions in systemic management of gastroenteropancreatic neuroendocrine tumours
Speaker 3 Juan Valle, UK
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Sunday, 10 September 2017, 14:45-16:15 90 mins
Title symposium Recent advances in endocrine malignancies
Chair Speaker TBC
Co-Chair Jaume Capdevila, ES
Title presentation 1 Introduction
Speaker 1 Chair
Lecture time 1 5’
Title presentation 2 Medullary thyroid cancer
Speaker 2 Jaume Capdevila, ES
Lecture/disc time 2 20’
Title presentation 3 Malignant pheochromocytoma and paraganglioma
Speaker 3 Joakim Crona, SE
Lecture/disc time 3 20’
Title presentation 4 Adrenocortical tumours
Speaker 4 Alfredo Berruti, IT
Lecture/disc time 4 20’
Title presentation 5 Differentiated thyroid carcinoma
Speaker 5 Barbara Jarzab, PL
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Jaume Capdevila, ES
Lecture/disc time 6 5’
Multidisciplinary Session Saturday, 9 September 2017, 09:30-10:30 60 mins
Title Midgut neuroendocrine tumour progressing on 1st line somatostatin analog: What treatment approach?
Chair Jonathan Strosberg, US
Panel Thierry de Baere, FR
Title presentation 1 Presentation of case/condition:
Systemic therapies for tumour and syndrome control
Speaker 1 Jonathan Strosberg, US
Title presentation 2 Peptide receptor radionuclide therapy
Speaker 2 Speaker TBC
Title presentation 3 Hepatic transarterial embolisation: When should it be recommended and which product should be selected?
Speaker 3 Thierry de Baere, FR
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Non-metastatic NSCLC and other thoracic malignancies
Challenge your Expert Saturday, 9 September 2017, 08:00-09:00 45 mins
Final Title Multimodality therapy of early stage mesothelioma
Chair Paul Van Schil, BE
Speaker Paul Baas, NL
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Monday, 11 September 2017, 16:30-18:00 90 mins
Title Lung cancer screening
Chair Kristiaan Nackaerts, BE
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Overview of clinical trials: What are the randomised data?
Speaker 1 Kristiaan Nackaerts, BE
Lecture time 25’
Title presentation 2 Implementation issues of lung cancer screening in Europe
Speaker 2 Ugo Pastorino, IT
Lecture time 25’
Title presentation 3 Biomarkers in lung cancer screening
Speaker 3 Luis Montuenga, ES
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Saturday, 9 September 2017, 09:15-10:45 90 mins
Title symposium Immunotherapy in thoracic malignancies: What can we expect in 2017?
Chair Johan Vansteenkiste, BE
Co-Chair Pilar Garrido, ES
Title presentation 1 Introduction
Speaker 1 Pilar Garrido, ES
Lecture time 1 5’
Title presentation 2 The role of immunotherapy in non-metastasic NSCLC
Speaker 2 Johan Vansteenkiste, BE
Lecture/disc time 2 20’
Title presentation 3 Upfront immune strategies in advanced NSCLC
Speaker 3 Naiyer Rizvi, US
Lecture/disc time 3 20’
Title presentation 4 Present and future of immunotherapy in small cell lung cancer
Speaker 4 Julie Brahmer, US
Lecture/disc time 4 20’
Title presentation 5 Is immunotherapy an option in mesothelioma?
Speaker 5 Joachim Aerts, NL
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Johan Vansteenkiste, BE
Lecture/disc time 6 5’
Multidisciplinary Session Sunday, 10 September 2017, 11:00-12:00 60 mins
Title Multidisciplinary approach to the management of stage III thymoma
Chair Marina Garassino, IT
Panel Robert J. Korst, US and Cecile Le Pechoux, FR
Title presentation 1 Presentation of case/condition and
The medical oncology perspective
Speaker 1 Marina Garassino, IT
Title presentation 2 The surgery perspective
Speaker 2 Robert J. Korst, US
Title presentation 3 The radiation therapy perspective
Speaker 3 Cecile Le Pechoux, FR
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
NSCLC, metastatic
Challenge your Expert Monday, 11 September 2017, 08:00-09:00 45 mins
Final Title Do we need to test for PD-L1 and how do we choose?
Chair Martin Reck, DE
Speaker Keith Kerr, UK
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Monday, 11 September 2017, 14:45-16:15 90 mins
Title Challenges in oncogene addicted NSCLC
Chair Solange Peters, CH
Co-Chair Pasi Jänne, US
Title presentation 1 New drivers, new perspectives
Speaker 1 Tony S.K. Mok, HK, CN
Lecture time 25’
Title presentation 2 Strategies against mechanisms of resistance
Speaker 2 Pasi Jänne, US
Lecture time 25’
Title presentation 3 The role of immunotherapy in oncogene addicted NSCLC
Speaker 3 Solange Peters, CH
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Saturday, 9 September 2017, 11:00-12:30 90 mins
Title symposium Oligometastatic NSCLC
Chair Suresh Senan, NL
Co-Chair Sanjay Popat, UK
Title presentation 1 Introduction
Speaker 1 Sanjay Popat, UK
Lecture time 1 5’
Title presentation 2 Definitions and implications of oligometastatic disease
Speaker 2 Wilfried Eberhardt, DE
Lecture/disc time 2 20’
Title presentation 3 Management of oligometastasis in patients with driver oncogenes (EGFR/ALK)
Speaker 3 Lecia Sequist, US
Lecture/disc time 3 20’
Title presentation 4 Pro-cons of choice of ablative modality (surgery, SABR, RFA)
Speaker 4 Suresh Senan, NL
Lecture/disc time 4 20’
Title presentation 5 Controversies and ongoing clinical trials
Speaker 5 Anne Marie Dingemans, NL
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Suresh Senan, NL
Lecture/disc time 6 5’
Multidisciplinary Session Saturday, 9 September 2017, 16:30-17:30 60 mins
Title Brain progression on targeted therapies and immunotherapies
Chair Suresh Senan, NL
Panel Ho-Shin Gwak, KR and Lecia Sequist, US
Title presentation 1 Presentation of case/condition and
The radiation therapy perspective
Speaker 1 Suresh Senan, NL
Title presentation 2 The neurosurgery perspective
Speaker 2 Ho-Shin Gwak, KR
Title presentation 3 The medical oncology perspective
Speaker 3 Lecia Sequist, US
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Public health and health economics
Challenge your Expert Monday, 11 September 2017, 08:00-09:00
Final Title The new EU Clinical Trials and Data Protection Regulations
Chair Christian Dittrich, AT
Speaker Anastassia Negrouk, BE
Lecture/disc time Presentation 10-15’ plus 35-30’ Discussion
Educational session Monday, 11 September 2017, 14:45-16:15 90 mins
Title The “micro-economics” of cancer: How the medical oncologist should micro-manage limited resources
Chair Franccesco de Lorenzo, IT
Co-Chair Paolo G. Casali, IT
Title presentation 1 The ethics of micro-allocation of limited resources “bedside rationing”
Speaker 1 Daniel Strech, DE
Title presentation 2 Micro-allocation of limited resources in the clinic
Speaker 2 Paolo G. Casali, IT
Title presentation 3 How should the medical oncologist negotiate with local health administrators
Speaker 3 Jose Maria Borras, ES
Lecture/disc time Presentations 25’ each plus 15’ Discussion
Special symposium Monday, 11 September 2017, 11:00-12:30 90 mins
Title symposium Access to innovative drugs in the EU
Chair Rosa Giuliani, IT
Co-Chair Maarten IJzerman, NL
Title presentation 1 Introduction
Speaker 1 Maarten IJzerman, NL
Lecture time 1 5’
Title presentation 2 Challenges in clinical research methodology
Speaker 2 Paolo Bruzzi, IT
Lecture/disc time 2 20’
Title presentation 3 Challenges in regulation
Speaker 3 Rosa Giuliani, IT
Lecture/disc time 3 20’
Title presentation 4 Challenges in reimbursement
Speaker 4 Maarten IJzerman, NL
Lecture/disc time 4 20’
Title presentation 5 The European cancer patient’s perspective
Speaker 5 Bettina Ryll, SE
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Rosa Giuliani, IT
Lecture/disc time 6 5’
Special session instead of MS Sunday, 10 September 2017, 09:30-10:30
Topic The “macro-economics” of cancer
Chair Alex Eniu, RO
Co-Chair Franco Cavalli, CH
Title presentation 2 Global discrepancies in cancer outcomes
Speaker 2 Peter Boyle, FR
Title presentation 3 Access to essential drugs
Speaker 3 Alex Eniu, RO
Title presentation 1 Cancer macroeconomics: Policy and politics
Speaker 1 José M. Martin-Moreno, ES
Lecture/disc time Each speaker c. 20’
Sarcoma
Challenge your Expert Saturday, 9 September 2017, 09:30-10:30 45 mins
Final Title Adjuvant systemic therapy in STS and GIST for whom?
Chair Robin Jones, UK
Speaker Silvia Stacchiotti, IT
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Sunday, 10 September 2017, 14:45-16:15 90 mins
Title State of the art in the treatment of soft tissue sarcoma: ESMO guidelines
Chair Rick Haas, NL
Co-Chair Heikki Joensuu, FI
Title presentation 1 Histological and molecular classification
Speaker 1 Paolo Dei Tos, IT
Lecture time 25’
Title presentation 2 Local treatment and strategy
Speaker 2 Sylvie Bonvalot, FR
Lecture time 25’
Title presentation 3 Systemic treatment: What the patient needs to know
Speaker 3 Javier Martin Broto, ES
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Saturday, 9 September 2017, 16:30-18:00 90 mins
Title symposium State of the science of targeted treatment in sarcoma
Chair George Demetri, US
Co-Chair Robin Jones, UK
Title presentation 1 Introduction
Speaker 1 George Demetri, US
Lecture time 1 5’
Title presentation 2 Managing GIST resistance to standard TKI therapy
Speaker 2 Heikki Joensuu, FI
Lecture/disc time 2 20’
Title presentation 3 Inhibitors of MDM2, CDK4 and other approaches in MDM2 amplified sarcomas
Speaker 3 Olivier Mir, FR
Lecture/disc time 3 20’
Title presentation 4 Immuno-oncology approaches to sarcomas
Speaker 4 Robert Maki, US
Lecture/disc time 4 20’
Title presentation 5 Next generation targets and combinations in sarcomas
Speaker 5 George Demetri, US
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Robin Jones, UK
Lecture/disc time 6 5’
Multidisciplinary Session Sunday, 10 September 2017, 11:00-12:00 60 mins
Title Challenges and complex presentations: Non resectable bone sarcoma
Chair A. Paolo dei Tos, IT
Panel Rick Haas, NL - Andreas Leithner, AT and Winette van der Graaf, UK
Title presentation 1 Presentation of case/condition and
The pathology perspective
Speaker 1 A. Paolo dei Tos, IT
Title presentation 2 The radiation therapy perspective
Speaker 2 Rick Haas, NL
Title presentation 3 The surgery perspective
Speaker 3 Andreas Leithner, AT
Title presentation 4 The medical oncology perspective
Speaker 4 Winette van der Graaf, UK
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Supportive and palliative care
Challenge your Expert Saturday, 9 September 2017, 08:00-09:00 45 mins
Final Title Practical management of toxicities of immunotherapy in cancer patients
Chair Paolo Ascierto, IT
Speaker Benjamin Besse, FR
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Sunday, 10 September 2017, 16:30-18:00 90 mins
Title Complications and toxicities: Tips for daily practice
Chair Joern Herrstedt, DK
Co-Chair Kazuo Tamura, JP
Title presentation 1 Skin toxicities: Prevention and management
Speaker 1 Caroline Robert, FR
Lecture time 20’
Title presentation 2 Management of opioid induced nausea and vomiting
Speaker 2 Declan Walsh, IE
Lecture time 20’
Title presentation 3 Bone metastases: How to evaluate the fracture risk: Surgery? Cementoplasty? Radiation?
Speaker 3 Hiroyuki Shibata, JP
Lecture time 20’
Title presentation 4 Rehabilitation and nutritional support for patients with advanced cancer
Speaker 4 Jan Arends, DE
Lecture time 20’
Title presentation 5 Discussion
Lecture time 10’
Special symposium Monday, 11 September 2017, 09:15-10:45 90 mins
Title symposium Are grade III / IV toxicities the only ones that matter?
Chair Matti Aapro, CH
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Introduction
Speaker 1 Co-chair
Lecture time 1 5’
Title presentation 2 Why do grade I/II toxicities matter
Speaker 2 Bostjan Seruga, SI
Lecture/disc time 2 20’
Title presentation 3 What toxicities matter to the patients
Speaker 3 Charlotte Roffiaen, IT
Lecture/disc time 3 20’
Title presentation 4 How does EMA look at toxicity/benefit ratios in cancer treatment
Speaker 4 Francesco Pignatti, UK
Lecture/disc time 4 20’
Title presentation 5 Drug interactions that matter
Speaker 5 Trine Lembrecht Jørgensen, DK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and perspectives
Speaker 6 Matti Aapro, CH
Lecture/disc time 6 5’
Multidisciplinary Session Saturday, 9 September 2017, 15:00-16:00 60 mins
Title Vomiting: one symptom, many causes
Chair Stein Kaasa, NO
Panel Christina Ruhlman DK and Riccardo Audisio, UK
Title presentation 1 Presentation of case/condition and
The general perspective
Speaker 1 Stein Kaasa, NO
Title presentation 2 The clinical and medical oncology perspective
Speaker 2 Christina Ruhlman DK
Title presentation 3 The surgery perspective
Speaker 3 Riccardo Audisio, UK
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Translational research
Challenge your Expert Sunday, 10 September 2017, 08:00-09:00 45 mins
Final Title How a tumour's microenvironment may affect therapeutic response
Chair Sergio Quezada, UK
Speaker Jeffrey Pollard, UK
Lecture time 5'-10’
Discussion Led by Chair
Lecture time 35’-40’
Educational session Friday, 8 September 2017, 16:00-17:30 90 mins
Title Genome instability, its relevance to cancer and therapeutic potential
Chair Serena Nik-Zainal, UK
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 What is DNA replication stress and what is its relevance to cancer?
Speaker 1 Jiri Bartek, DK
Lecture time 25’
Title presentation 2 Aneuploidy and cancer
Speaker 2 Tom Watkins, UK
Lecture time 25’
Title presentation 3 Kateagis and Apobec- relevance to cancer
Speaker 3 Serena Nik-Zainal, UK
Lecture time 25’
Title presentation 4 Discussion
Lecture time 15’
Special symposium Monday, 11 September 2017, 14:45-16:15 90 mins
Title symposium Cancer evolution and metastasis: From single cells to population dynamics
Chair Ivana Bozic, US
Co-Chair Raffaella Giavazzi, IT
Title presentation 1 Introduction
Speaker 1 Raffaella Giavazzi, IT
Lecture time 1 5’
Title presentation 2 Phylogenetic modeling of cancer cell populations
Speaker 2 Ivana Bozic, US
Lecture/disc time 2 20’
Title presentation 3 Quantifying the evolutionary dynamics of tumor growth and metastasis
Speaker 3 Christina Curtis, US
Lecture/disc time 3 20’
Title presentation 4 Metastasis as an evolutionary process
Speaker 4 Samra Turajlic, UK
Lecture/disc time 4 20’
Title presentation 5 Single cell analysis and cancer
Speaker 5 Thierry Voet, UK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Ivana Bozic, US
Lecture/disc time 6 5’
Multidisciplinary Session Sunday, 10 September 2017, 16:30-17:30 60 mins
Title Managing colorectal cancer evolution
Chair Alberto Bardelli, IT
Panel Rodrigo Dienstmann, ES and Sabine Tejpar, BE
Title presentation 1 Presentation of case/condition and
Colorectal cancer evolution in response to treatment. Evolving intra-tumour
heterogeneity
Speaker 1 Alberto Bardelli, IT
Title presentation 2 Classification and molecular diagnosis of colorectal cancer. Inter-tumour heterogeneity
Speaker 2 Rodrigo Dienstmann, ES
Title presentation 3 Clinical implications of inter- and intra-tumour heterogeneity
Speaker 3 Sabine Tejpar, BE
Lecture time 20-30’: Case/condition presentation and Panel discussion
40-30’: Audience discussion and Q&A
Congress highlights Congress Highlights Session 1 – The best of the Madrid 2017 Congress Tuesday, 12 September 2017 – 09:00-12:40 Chair part 1: Richard Marais, UK Chair part 2: Fortunato Ciardiello, IT
09:00 20 Basic science Anton Berns, NL
09:20 20 Translational research Ilaria Malanchi, UK
09:40 30 GU tumours Aurelius Omlin, CH
10:10 20 CNS tumours Matthias Preusser, AT
10:30 20 Break
10:50 20 Head and neck cancer Jean-Pascal Machiels, BE
11:20 20 Developmental therapeutics Jan Schellens, NL
11:40 30 Breast cancer early and metastatic Giuseppe Curigliano, IT
12:10 30 Thoracic malignancies Luis Paz-Ares, ES
12:40 CLOSE
Congress Highlights Session 2 – The best of the Madrid 2017 Congress Tuesday, 12 September 2017 – 09:00-12:30 Chair part 1: Alberto Sobrero, IT Chair part 2: Josep Tabernero, ES
09:00 20 GI colorectal Richard Adams, UK
09:20 30 GI non-colorectal and NETs and endocrine tumours (merged)
Michel Ducreux, FR
09:50 20 Sarcoma Hans Gelderblom, NL
10:10 20 Gynaecological cancers Domenica Lorusso, IT
10:30 20 Break
10:50 20 Supportive and palliative care Florian Scotté, FR
11:10 20 Public health and health economics Carin Uyl-de Groot, NL
11:30 20 Haematological malignancies Frederic Peyrade, FR
11:50 20 Immunotherapy of cancer Inge Marie Svane, DK
12:10 20 Melanoma and other skin tumours Salvador Martin Algarra, ES
12:30 CLOSE
Joint Symposia
ESMO-EACR
Friday, 8 September 2017, 14:00-15:30 90 mins (1h30)
Title symposium Preclinical models for developing combination therapeutics
Co-Chair Fortunato Ciardiello, IT
Co-Chair Anton Berns, NL
Introduction – 5’ Fortunato Ciardiello, IT
Title presentation 1 Tumour organoids to test drug responses
Speaker 1 Matthew Garnett,UK
Lecture time 1 20’
Title presentation 2 The Achilles heel of acquired drug resistance
Speaker 2 René Bernards, NL
Lecture time 2 20’
Title presentation 3 Optimising drug combinations to overcome resistance
Speaker 3 Ryan Corcoran, US
Lecture time 3 20’
Title presentation 4 Accelerated clinical evaluation of drug combinations based on biological insight
Speaker 4 Josep Tabernero, ES
Lecture time 4 20’
Conclusion – 5’ Anton Berns, NL
ESMO-ESP Friday, 8 September 2017, 14:00-15:30 90 mins (1h30)
Title symposium The evolution of pathological reporting: GI focus Co-Chair Dirk Arnold, PT Co-Chair Pierre Bedossa, FR Introduction – 5’ Pierre Bedossa, FR Title presentation 1 The clinician’s perspective: What is expected from the pathologist? Speaker 1 Dirk Arnold, PT Lecture time 1 20’ Title presentation 2 Pathologist: From descriptive to synoptic reports Speaker 2 Iris D. Nagtegaal, NL Lecture time 2 20’ Title presentation 3 Molecular pathology in GI cancer: What is useful and how to integrate
it into the pathological report
Speaker 3 Thomas Kirchner, DE Lecture time 3 20’ Title presentation 4 Immunology in GI cancer: What is useful and how to integrate it into
the pathological report
Speaker 4 Cecile Badoual, FR Lecture time 4 20’ Conclusion –5’ Dirk Arnold, PT
ESMO-ESOP
Friday, 8 September 2017, 14:00-15:30 90 mins (1h30)
Title symposium The growing need for collaboration between clinicians and oncology pharmacists
Co-Chair Stefan Rauh, LU
Co-Chair Klaus Meier, DE
Introduction – 5’ Stefan Rauh, LU
Title presentation 1 Access to anti-cancer medicines: How Germany is tackling the issue
Speaker 1 Bernhard Wörmann, DE
Lecture time 1 20’
Title presentation 2 Contamination of health professionals in the oncology ward
Speaker 2 Ewelina Korczowska, PL
Lecture time 2 20’
Title presentation 3 Challenges in adherence to oral cancer therapies: The clinician’s perspective
Speaker 3 Stefan Rauh, LU
Lecture time 3 20’
Title presentation 4 Challenges in adherence to oral cancer therapies: The oncology pharmacist’s perspective
Speaker 4 Klaus Meier, DE
Lecture time 4 20’
Conclusion – 5’ Klaus Meier, DE
ESMO-WHO
Friday, 8 September 2017, 14:00-15:30 90 mins (1h30)
Title symposium Workforce optimisation: Results of the WHO-ESMO study on health workforce requirements for breast cancer care
Co-Chair Alexandru Eniu, RO
Co-Chair James Campbell, CH
Introduction & Title presentation 1
What works in workforce optimization: The WHO perspective
Speaker 1 James Campbell, CH
Lecture time 1 15’
Title presentation 2 It’s about the people: Assessing the gaps and planning the workforce for breast cancer care
Speaker 2 Alexandru Eniu, RO
Lecture time 2 15’
Title presentation 3 The WHO-ESMO Health Workforce Survey: Preliminary results from Italy
Speaker 3 Giuseppe Curigliano, IT
Lecture time 3 15’
Title presentation 4 WHO-ESMO Health Workforce Survey: What is different in Spain?
Speaker 4 Miguel Martin, ES
Lecture time 4 15’
Title presentation 5 Participant discussion and Q&A
Speaker 5 James Campbell, CH
Lecture time 5 25’
Conclusion – 5’ Alexandru Eniu, RO
ESMO-KACO
Friday, 8 September 2017, 16:00-17:30 90 mins (1h30)
Title symposium Molecular targets in breast cancer
Co-Chair Christoph Zielinski, AT
Co-Chair Young-Hyuck Im, KR
Introduction – 5’ Young-Hyuck Im, KR
Title presentation 1 Molecular targets in overcoming treatment resistance
Speaker 1 Christoph Zielinski, AT
Lecture time 1 20’
Title presentation 2 Optimising treatment for luminal breast cancer: Luminal A vs. Luminal B
Speaker 2 Sung Bae Kim, KR
Lecture time 2 20’
Title presentation 3 Developing strategies for overcoming drug resistance in HER2–positive breast cancer
Speaker 3 Seock-Ah Im, KR
Lecture time 3 20’
Title presentation 4 Molecular divergence in an ‘entity’?: Triple-negative breast cancer
Speaker 4 Fabrice André, FR
Lecture time 4 20’
Conclusion – 5’ Christoph Zielinski, AT
ESMO-ASCO
Friday, 8 September 2017, 16:00-17:30 90 mins (1h30)
Title symposium Evidence from single-arm trials
Co-Chair Fortunato Ciardiello, IT
Co-Chair Bruce E. Johnson, US
Introduction – 5’ Fortunato Ciardiello, IT
Title presentation 1 The settings and the challenges of single-arm trials
Speaker 1 Paolo G. Casali, IT
Lecture time 1 – 20’
Title presentation 2 Evidence from single-arm trials that lead to regulatory approval
Speaker 2 E. Johnson, US
Lecture time 2 – 20’
Title presentation 3 Early clinical data for new drug approval in Europe: Help or hindrance?
Speaker 3 Francesco Pignatti, UK
Lecture time 3 – 20’
Title presentation 4 The FDA perspective (TBC)
Speaker 4 Gideon Blumenthal, US
Lecture time 4 – 20’
Conclusion – 5’ Bruce E. Johnson, US
ESMO-JSMO
Friday, 8 September 2017, 16:00-17:30 90 mins (1h30)
Title symposium Combinations with immuno-oncology agents for gastrointestinal cancer: Which ones make the best partners?
Co-Chair Josep Tabernero, ES
Co-Chair Hironobu Minami, JP
Introduction – 5’ Josep Tabernero, ES
Title presentation 1 Combinations with immune-oncology agents for GI cancers: Their scientific rationales
Speaker 1 Kohei Shitara, JP
Lecture time 1 20’
Title presentation 2 Combinations of checkpoint inhibitors and immunostimulation for immune-ignorant tumours
Speaker 2 Ignacio Melero, ES
Lecture time 2 20’
Title presentation 3 Combinations with immune-oncology agents for upper GI cancers: Update of clinical trial results
Speaker 3 Kei Muro, JP
Lecture time 3 20’
Title presentation 4 Combinations with immune-oncology agents for colorectal cancer: Current status of clinical development
Speaker 4 Josep Tabernero, ES
Lecture time 4 20’
Conclusion – 5’ Hironobu Minami, JP
ESMO-EONS
Friday, 8 September 2017, 16:00-17:30 90 mins (1h30)
Title symposium Promoting patient safety at clinical and organisational levels
Co-Chair George Pentheroudakis, GR
Co-Chair Daniel Kelly, UK
Introduction – 5’ George Pentheroudakis, GR
Title presentation 1 Patient safety at the clinical and organisational level
Speaker 1 Daniel Kelly, UK
Lecture time 1 20’
Title presentation 2 Promoting safety for cancer patients: The ESMO-EONS Guidelines for the management of extravasation
Speaker 2 J. A. Pérez Fidalgo, ES
Lecture time 2 20’
Title presentation 3 Ethical and financial dimensions of patient safety
Speaker 3 Stefan Rauh, LU
Lecture time 3 20’
Title presentation 4 Evidence of the impact of nursing interventions on patients with cancer: results from a systematic review
Speaker 4 Mary Wells, UK
Lecture time 4 20’
Conclusion – 5’ Daniel Kelly, UK
ESMO-IPOS Saturday, 9 September 2017, 11:00-12:30 90 mins (1h30)
Title symposium Working together to prevent professional burnout and improve patient care
Co-Chair Susana Banerjee, UK
Co-Chair Luzia Travado, PT
Introduction – 5’ Luzia Travado, PT
Title presentation 1 Burnout: The scale of the problem facing oncology professionals
Speaker 1 Susana Banerjee, UK
Lecture time 1 15’
Title presentation 2 Communication skills with cancer patients: Improving patient experience
Speaker 2 Lesley Fallowfield, UK
Lecture time 2 15’
Title presentation 3 The value of psychosocial care for cancer patients
Speaker 3 Luzia Travado, PT
Lecture time 3 15’
Title presentation 4 Psychosocial interventions to reduce professional burnout
Speaker 4 Maria Die Trill, ES
Lecture time 4 15’
Panel Discussion – 25’ Matthias Preusser, AT Jan Geissler, DE
ESMO-ESTRO
Saturday, 9 September 2017, 14:45-16:15 90 mins (1h30)
Title symposium Lung cancer: Recent developments of multimodal treatments
Co-Chair Solange Peters, CH
Co-Chair Yolande Lievens, BE
Introduction – 5’ Solange Peters
Title presentation 1 How to integrate radiotherapy innovations in the multimodality treatment of LA-NSCLC?
Speaker 1 Corinne Faivre Finn, UK
Lecture time 1 – 20’
Title presentation 2 Standard and perspectives for systemic treatments in stage 3?
Speaker 2 Pilar Garrido, ES
Lecture time 2 – 20’
Title presentation 3 Oligometastatic NSCLC: What are the treatment paradigms and how does radiotherapy fit in?
Speaker 3 Matthias Guckenberger, CH
Lecture time 3 – 20’
Title presentation 4 Oligometastatic NSCLC: When and how to combine systemic therapy and radiotherapy?
Speaker 4 Linda Coate, UK
Lecture time 4 – 20’
Conclusion – 5’ Yolande Lievens, BE
ESMO-SIOPE
Saturday, 9 September 2017, 14:45-16:15 90 mins (1h30)
Title symposium Tumours at the edge of paediatric and adult oncology: Emphasising collaboration
Co-Chair Giannis Mountzios, GR
Co-Chair Stefan Bielack, DE
Introduction – 5’ Giannis Mountzios, GR
Title presentation 1 Bone and soft tissue sarcomas in AYA as models of multidisciplinary management
Speaker 1 Stefan Bielack, DE
Lecture time 1 20’
Title presentation 2 Leukaemias-Lymphomas: New insights from paediatric leukaemia research and clinical trials
Speaker 2 Arend von Stackelberg, DE
Lecture time 2 20’
Title presentation 3 CNS tumours in AYA: Overcoming obstacles with multidisciplinary care
Speaker 3 Evi Razis, GR
Lecture time 3 20’
Title presentation 4 Mapping the cancer care for AYA in Europe: Current status and needs
Speaker 4 Dan Stark, UK
Lecture time 4 20’
Conclusion – 5’ Stefan Bielack, DE
ESMO-EORTC-EACR
Sunday, 10 September 2017, 11:00-12:30 90 mins (1h30)
Title symposium Tumours with rare oncogenic lesions: From pre-clinical to clinical validation
Co-Chair Rolf Stahel, CH
Co-Chair Anton Berns, NL
Co-Chair Roger Stupp, CH
Introduction – 5’ Anton Berns, NL
Title presentation 1 Targeting the stem of cancer: inhibition of the WNT pathway in colorectal tumours
Speaker 1 Alberto Bardelli, IT
Lecture time 1 20’
Title presentation 2 Using rare mutations to guide treatment options for drug resistant melanoma
Speaker 2 Richard Marais, UK
Lecture time 2 20’
Title presentation 3 Vulnerabilities of gliomas with IDH1 mutations
Speaker 3 Daniel Cahill, US
Lecture time 3 20’
Title presentation 4 Biomarkers for PARP responders
Speaker 4 Laura van‘t Veer, US
Lecture time 4 20’
Conclusion – 5’ Roger Stupp, CH
ESMO-CSCO
Sunday, 10 September 2017, 11:00-12:30 90 mins (1h30)
Title symposium Liquid biopsy in the clinic: From myth to reality
Co-Chair Fortunato Ciardiello, IT
Co-Chair Yi-Long Wu, CN
Introduction – 5’ Fortunato Ciardiello, IT
Title presentation 1 Technologic advances in liquid biopsy: East meets West
Speaker 1 Xu-Chao Zhang, CN
Lecture time 1 20’
Title presentation 2 Next generation sequencing and liquid biopsy
Speaker 2 Nicola Normanno, IT
Lecture time 2 20’
Title presentation 3 Clinical application of liquid biopsy in management of advanced NSCLC
Speaker 3 Wang Shuhang, CN
Lecture time 3 20’
Title presentation 4 Clinical application of liquid biopsy in management of colorectal cancer
Speaker 4 Clara Montagut, ES
Lecture time 4 20’
Conclusion – 5’ Yi-Long Wu, CN
ESMO-SEOM Joint Session
Monday, 11 September 2017 – 09:15-10:45 90 mins (1h30)
Title symposium Integrating biomarkers into oncology
Co-Chair Fortunato Ciardiello, IT
Co-Chair Miguel Martin, ES
Introduction – 5’ Miguel Martin, ES
Title presentation 1 General vision of biomarkers in oncology: Design of clinical studies for biomarker discovery
Speaker 1 José Luis Pérez Gracia, ES
Lecture time 1 – 20’
Title presentation 2 Biomarkers in breast cancer
Speaker 2 Aleix Prat, ES
Lecture time 2 – 20’
Title presentation 3 Biomarkers in lung cancer
Speaker 3 Solange Peters, CH
Lecture time 3 – 20’
Title presentation 4 Biomarkers in unknown origin cancer
Speaker 4 Manel Esteller, ES
Lecture time 4 – 20’
Conclusion – 5’ Fortunato Ciardiello, IT
ESMO-MASCC
Monday, 11 September 2017 – 11:00-12:30 90 mins (1h30)
Title symposium Emerging issues in cancer supportive care and survivorship
Co-Chair Nathan Cherny, IL
Co-Chair Ian Olver, AU
Introduction – 5’ Nathan Cherny, IL
Title presentation 1 Safe monitoring of immunotherapy
Speaker 1 Ian Olver, AU
Lecture time 1 – 20’
Title presentation 2 Steroids and supportive care
Speaker 2 Nathan Cherny, IL
Lecture time 2 – 20’
Title presentation 3 Financial toxicity
Speaker 3 Richard Sullivan, UK
Lecture time 3 –’ 20
Title presentation 4 Return to work after cancer
Speaker 4 Luis Pimentel, PT
Lecture time 4 – 20’
Conclusion – 5’
ESMO-ESOI joint session
Monday, 11 September 2017 – 14:45-16:15 90 mins (1h30)
Title symposium Colorectal cancer imaging: New opportunities to guide treatment decisions
Co-Chair Emile Voest, NL
Co-Chair Regina Beets-Tan, NL
Session Learning Objectives: ✓ To learn about new treatment options in Rectal Cancer and the
role of functional MR imaging ✓ To learn about MR liver specific contrast and MR imaging
biomarkers for the detection and treatment response evaluation of liver metastases
✓ To know the evidence of interventional treatment for CRC liver mets and learn about its position relative to surgical and systemic treatment
✓ To learn about PET/MRI whole body Imaging and understand whether it is ready for clinical practice
Intro- 5` Emile Voest, NL
Title presentation 1 Rectal cancer: Organ preservation and the role of imaging
Speaker 1 Regina Beets-Tan, NL
Lecture time 1 – 20’ ✓ To learn about organ preserving treatment for rectal ca patients with complete response to neoadjuvant chemoradiotherapy
✓ To understand the critical issues when selecting patients for organ preservation
✓ To know the role of MR imaging for the selection and follow up of these patients
✓ To learn about the performance of MRI for identifying viable disease in bowel wall and nodes.
Title presentation 2 CRC liver metastases: Detection & treatment response evaluation with modern imaging
Speaker 2 Daniele Regge, IT
Lecture time 2 – 20’ ✓ To learn about MRI using liver specific contrast for the detection of liver metastases and know its performance relative to CT
✓ To propose a cost-effective algorithm for the pre-treatment staging of CRC liver metastases
✓ To learn about MR imaging biomarkers and its potential role for treatment response evaluation
Title presentation 3 CRC liver metastases: Interventional treatment
Speaker 3 Thomas Helmberger, DE
Lecture time 3 – 20’ ✓ To know the evidence of interventional treatment for CRC liver-dominant metastatic disease
✓ To review the indications, complications, and outcome of ablation therapy, chemo- and radio-embolization of CRC liver metastases
✓ To understand its position relative to surgical and systemic treatment
Title presentation 4 PET/MRI: Combining molecular and functional imaging
Speaker 4 Vicky Goh, UK
Lecture time 4 – 20’
✓ To learn about integrated PET/MRI, its technical challenges and potential advantages including its multi-parametric ability
✓ To understand how integrated PET/MRI may be used to detect recurrent disease in CRC, predict and assess response to therapy
✓ To know whether integrated PET/MRI is ready for clinical practice
Conclusion – 5’ Regina Beets-Tan, NL
ESMO Clinical Practice Guidelines
Sunday 10 September 2017, 10:45-12:45
CHAIRS 0A Intro 10 mins George Pentheroudakis, GR
0B Questionnaire 10 mins Cristiana Sessa, CH
Resectable locally advanced oesophagogastric cancer
1A Speaker 10 mins Elizabeth Smyth, UK
1B Discussant 10 mins Florian Lordick, DE
Renal cancer: sequence of therapies, immunotherapy
1C Speaker 10 mins Lisa Derosa, IT
1D Discussant 10 mins Bernard Escudier, FR
Management of carcinomatous meningitis in patient with advanced lung adeno
1E Speaker 10 mins Emilie Le Rhun, FR
1F Discussant 10 mins Matthias Preusser, AT
Early stage NSCLC 1G Speaker 10 mins Alessandra Curioni, CH
1H Discussant 10 mins Pieter Postmus, UK
Sunday 10 September 2017, 14:30-16:30
CHAIRS 0A Intro 10 mins George Pentheroudakis, GR
0B Questionnaire 10 mins Cristiana Sessa, CH
Patient with metastatic breast cancer: sequence of therapies
2A Speaker 10 mins Carmen Criscitiello, IT
2B Discussant 10 mins Nadia Harbeck, DE
BRCA mutation carrier patient: how to manage? 2C Speaker 10 mins
Katarzyna Sosińska-Mielcarek, PL
2D Discussant 10 mins Shani Paluch-Shimon, IL
Hodgkin lymphoma 2E Speaker 10 mins Jemma Longley, UK
2F Discussant 10 mins Stefano Luminari, IT
Immunotherapy in melanoma, pseudoprogression, management of toxicities
2G Speaker 10 mins Emanuela Romano, FR
2H Discussant 10 mins Ulrich Keilholz, DE
Special sessions
Special session Saturday, 9 September 2017, 09:15-10:45 90 mins
Title Access to novel targeted therapies and clinical trials in Europe
Chair Josep Tabernero, ES
Co-Chair Tanja Cufer, SI
Title presentation 1 Introduction
Speaker 1 Josep Tabernero, ES
Lecture time 1 5’
Title presentation 2 Access to molecular diagnosis: The French model
Speaker 2 Fabrice Barlesi, FR
Lecture time 2 20’
Title presentation 3 Inequalities in access to treatment
Speaker 3 Tanja Cufer, SI
Lecture/disc time 3 20’
Title presentation 4 The patient’s view
Speaker 4 Fredrik Johansson, SE
Lecture/disc time 4 20’
Title presentation 5 Drug repurposing: New tricks for old drugs
Speaker 5 René Bernards, NL
Lecture/disc time 5 20’
Title presentation 6 Conclusions
Speaker 5 Tanja Cufer, SI
Lecture/disc time 5 10’
Practising Oncologists Committee Sunday, 10 September 2017, 11:00-12:30 90 mins
Title symposium
How to conciliate the fast moving genetic landscape with everyday practice and resources
Chair / Co-Chair
Stefan Rauh, LU
Co-Chair
Gabor Lakatos, HU
Title presentation 1
Introduction
Speaker 1
Gabor Lakatos, HU
Lecture time 1
5’
Title presentation 2
Overview of genetic testing: Evolution in the last 5 years
Speaker 2
István Peták, HU
Lecture time 2
20’
Title presentation 3
What has been included in present guidelines: Impact of inclusion on oncology practice
Speaker 3
Christian Rolfo, BE
Lecture time 3
20’
Title presentation 4
Integrating personalised medicine into oncology practice: The French experience
Speaker 4
Jean-Charles Soria, FR
Lecture time 4
20’
Title presentation 5 Round table
Panel discussion: What are the benefits of personalised medicine for oncology practice? How can it be integrated into everyday practice?
Speaker 5
All
Lecture time 5
20’
Title presentation 6
Conclusions
Speaker 6
Stefan Rauh, LU
Lecture time 6
5’
ESO Friday, 8 September 2017, 14:00-15:30 90 mins (1h30)
Title symposium
Primary and secondary prevention of cancer: Where do we stand?
Chair / Co-Chair
Alberto Costa, IT
Co-Chair
Jean-Yves Douillard, CH
Title presentation 1
Introduction
Speaker 1
Alberto Costa, IT
Lecture time 1
5’
Title presentation 2 The concept and achievements of prevention
Speaker 2 Andrea de Censi, IT
Lecture time 2
25’
Title presentation 3 Aspirin for prevention and adjuvant treatment of cancer
Speaker 3 Ruth Langley, UK
Lecture time 3
25’
Title presentation 4 Tobacco cessation and cancer incidence and recurrence
Speaker 4 Elisabeth Quoix, FR
Lecture time 4
25’
Title presentation 5
Conclusions
Speaker 5
Jean-Yves Douillard, CH
Lecture time 5
10’
MCBS Sunday, 10 September 2017 – 16:30-18:00 90 mins (1h30)
Title symposium Cost, value and assessment tools of therapies in modern oncology
Chair / Co-Chair Elisabeth De Vries, NL
Co-Chair Nathan Cherny, IL
Title presentation 1 Introduction
Speaker 1 Nathan Cherny, IL
Lecture time 1 5’
Title presentation 2 Principles and reflections on cost, value and sustainability of anticancer therapies
Speaker 2 Ian Tannock, CA
Lecture time 2 15’
Title presentation 3 ESMO Magnitude of Clinical Benefit Scale (MCBS): new version: 1.1
Speaker 3 Nathan Cherny, IL
Lecture time 3 15’
Title presentation 4 Integrating MCBS in ESMO Guidelines
Speaker 4 George Pentheroudakis, GR
Lecture time 4 15’
Title presentation 5 Implementation of the ESMO-MCBS scale
Speaker 5 Elisabeth De Vries, NL
Lecture time 5 15’
Title presentation 6 Discussion and conclusions, led by
Speaker 6 Elisabeth De Vries, NL
Lecture time 6 25’
Women 4 Oncology Saturday, 9 September 2017 – 11:00-12:30 90 mins (1h30)
Title symposium Women 4 Oncology
Chair / Co-Chair Solange Peters, CH
Co-Chair Frances Shepherd, CA
Title presentation 1 Numbers and perspectives: the situation of women medical oncologist
Speaker 1 Solange Peters, CH
Lecture time 1
10’
Title Round-Table Discussion 2
Round-table: Gender disparities in the medical field: the Basic Researches and Surgeon perspective
Panel Speaker 2
Solange Peters, CH - Josep Tabernero, ES – Caroline Dive, UK - Frances Shepherd, CA – Patricia Cornet, US
Moderator 2 Capitolina Diaz, ES
Lecture time 2 25’
Title presentation 3 How to address equal gender opportunities at a political level? What politicians can do
Speaker 3 Solange Peters, CH - Josep Tabernero, ES - Caroline Dive, UK - Frances Shepherd, CA – Patricia Cornet, US
Moderator 3 Amarelle Cesla, CH
Lecture time 3
25’
Title Round-Table Discussion 4
Discussion: Step by step: how could ESMO drive changes?
Speaker 4 Solange Peters, CH - Josep Tabernero, ES
Moderator 4 Frances Shepherd, CA
Lecture time 4 20’
Title presentation 5
W4O Award Presentation
Speaker 5 Christoph Zielinski,AT
Lecture time 5 2’
Title presentation 6 W4O Award Recipient (with PPT)
Speaker 6 Frances Shepherd, CA
Lecture time 6
8’
Title presentation 7
Q&A and Closing remarks
Speaker 7
Solange Peters, CH and Frances Shepherd, CA
Lecture time 7
5’
Special session Friday, 8 September 2017, 10:00-11:30 90 mins (1h30)
Title symposium
Medical oncology as a contributor to global policy: How to improve national cancer plans
Co-Chair (ESMO) Alex Eniu, RO
Co-Chair Lisa Stevens, USA
Title presentation 1 Introduction
Speaker 1 Lisa Lak, USA
Lecture time 1 5’
Title presentation 2
Overview of NCCP, including forming the multi-disciplinary and multi-sectoral partnership. - Highlight of ICCP and countries that have plans (and NCD plans)
Speaker 2 André Ilbawi, CH
Lecture time 2 15’
Title presentation 3
Example from Central Asia Leadership Forum -success of multi-disciplinary team -success for the country after developing a NCCP
Speaker 3 Dilyara Kaidarova, KZ
Lecture time 3 15’
Title presentation 4
Example from Central Europe -highlights from NCCP -goal for the future
Speaker 4 Jacek Jassem, PL
Lecture time 4
15’
Title presentation 5
Example from Eastern Europe -highlights from NCCP -goal for the future
Speaker 5 Sergey Krasnuy, BY
Lecture time 5 15’
Title presentation 6
Interactive Q&A Wrap up— -highlight specific points from the presentation -field questions from the audience -advertise the upcoming E Europe Leadership Forum
Speaker 6 Alex Eniu, RO
Lecture time 6 20’
Special session Saturday, 9 September 2017, 14:45-16:15 90 mins (1h30)
Title The incoming wave of biosimilars in Oncology
Chair Josep Tabernero, ES
Co-Chair Elena Wolff-Holz, DE
Title presentation 1 Introduction
Speaker 1 Josep Tabernero, ES
Lecture time 10’
Title presentation 2 Biosimilars: European Medicines Agency’s plan for healthcare professionals
Speaker 2 Juan Garcia Burgos, UK
Lecture time 10’
Title presentation 3 Clinician’s perspective: Building confidence to prescribe biosimilars – ESMO Position Paper on Biosimilars
Speaker 3 Rosa Giuliani, IT
Lecture time 10’
Title presentation 4 Collaborative approach key for uptake of biosimilars
Speaker 4 Gustaf Befrits, SE
Lecture time 10’
Title presentation 5 The crucial role of specialist nurses
Speaker 5 Johan Demunter, BE
Lecture time 10’
Title presentation 6 Patient’s perspective: What have we learned and what can be improved?
Speaker 6 Luisa Avedano, BE
Lecture time 10’
Title presentation 7 Oncology: Impact of biosimilars on the sustainability of healthcare systems
Speaker 7 Murray Aitken, US
Lecture time 10’
Panel discussion/Q&A All
20’
Young oncologists
YO Brunch 1 Saturday, 9 September 2017, 11:00-12:00 45 min
Title session Communicating with cancer patients in the era of personalised medicine
Speaker Gerald Prager, AT
Session Coordinators
Claudia Cardone, IT Mehmed Akif Ozturk, TR
Lecture/discussion time 45’
YO Brunch 2 Sunday, 10 September 2017, 11:00-12:00 45 min
Title session Burn out in young oncologists: How can we combat it?
Title presentation 1 Introduction to psychological stress and burn-out
Speaker 1 Francesca Fiore, IT
Time 20’
Title presentation 2 Prevalence and prevention of burn-out in young oncologists
Speaker 2 Susana Banerjee, UK
Lecture/discussion time 25’
Session coordinators Michiel Strijbos, BE Teresa Amaral, PT
YO Brunch 3 Monday, 11 September 2017, 11:00-12:00 45 min
Title session Critically ill cancer patients: Patient selection for admission to ICU
Title presentation 1 Which factors influence decision making for ICU admission in cancer patients?
Speaker 1 Peter Schellongowski, AT
Time 20’
Title presentation 2 Interactive case – case presentation
Speaker 2 Mehmed Akif Ozturk, TR
Time 5’
Title presentation 3 Interactive case discussion with the audience
Speaker 3 Peter Schellongowski, AT
Time 20’
Session Coordinators
Jesus Corral, ES Alexandra Tyulyandina, RU
YO session in collaboration with the ESMO Public Oncology Committee (POC) Saturday, 9 September 2017, 09:30-10:30 60 mins
Title Clinical cases of solid tumours: Discussion forum for practicing and young oncologists
Table topic 1 Metastatic colorectal cancer clinical case discussion (eg. 1st line choice in WT pts)
Speaker Erika Martinelli, IT
Session/table Coordinator Claudia Cardone, IT
Table topic 2 Unknown primary carcinoma clinical case discussion (eg. Bone lesions in elderly)
Speaker George Pentheroudakis, GR
Session/table Coordinator Michalis Karamouzis, GR
Table topic 3 Breast cancer, adjuvant setting, clinical case discussion (eg. Adjuvant systemic endocrine therapies in premenopausal patients and fertility prevention)
Speaker Olivia Pagani, CH
Session/table Coordinator Radu Vidra, RO
YO Session for medical students and new physicians Saturday, 9 September 2017, 15:00-16:00 60 min
Title ESMO for medical students and young physicians
Chair Andrés Cervantes, ES
Co-chair Anna Berghoff, AT
Title presentation 1 ESMO-ESO Medical Students Course
Speaker 1 Andrés Cervantes, ES
Title presentation 2 How to prepare and present your first poster at a congress
Speaker 2 Anna Berghoff, AT
Guided poster walk, led by 3 YOC members (up to 8-10 attendees per group)
Poster walk guide Matthias Preusser, AT Michiel Strijbos, BE Mila Petrova, BG
YO Masterclass
Sunday, 10 September 2017, 14:15-17:15 180 min. (incl. 20’ coffee break)
Title session Young oncologists and excellence in clinical research: ESMO YOC meets Methods in Clinical Cancer Research Workshop – MCCR – (ex-Flims)
Chair Matthias Preusser, AT, YOC chair
Co-chair Leticia De Mattos-Arruda, UK, Flims president
Title presentation 1 Understanding the design of clinical trials: Where to start?
Speaker 1 Johann de Bono, UK
Session Shooter 1 Jesus Corral, ES
Lecture/discussion time 40’ (25’presentation plus 15’ discussion)
Title presentation 2 Incorporation of immuno-biomarkers and immunotherapy in clinical trials
Speaker 2 Ignacio Melero, ES
Session Shooter 2 Teresa Amaral, PT
Lecture/discussion time 40’ (25’ presentation plus 15’ discussion)
Coffee Break 20’
Title presentation 3 Incorporation of genomics in clinical trials
Speaker 3 Fabrice André, FR
Session Shooter 3 Laurids Poulsen, DK
Lecture/discussion time 40’ (25’ presentation plus 15’ discussion)
Title presentation 4 Perspectives in clinical trials for the next decade
Speaker 4 Stefan Sleijfer, NL
Session Shooter 4 Alexandra Tyulyandina, RU
Lecture/discussion time 40’ (25’ presentation plus 15’ discussion)
Vesalius Talk and Cocktail Sunday, 10 September 2017, 17:30-18:45
75 min. (30 min talk + 45 min cocktail)
Title How active participation in ESMO has impacted my career
Speakers
Introduction and Moderator: Josep Tabernero, ES
Erika Martinelli, IT Raffaele Califano, UK Evandro De Azambuja, BE
Time 30’
Vesalius cocktail
Time 45’
YO Mentorship session Monday, 11 September 2017, 09:30-10:30 60 min
Title Your choice of career path in oncology
Session coordinator Laurids Poulsen, DK
Topic 1 Clinical oncology and palliative care
Speaker table 1 Stefan Rauh, LU
Speaker table 2 Michiel Strijbos, BE
Topic 2 Clinical and translational research
Speaker table 1 Fatima Cardoso, PT
Speaker table 2 Guillem Argiles Martinez, ES
Topic 3 Industry as a career path
Speaker table 1 Emmanuel Mitry, FR (Roche)
Speaker table 2 Michelle Rashford, US
Topic 4 Basic Science
Speaker table 1 Walter Berger, AT
Speaker table 2 Emmy Verschuren, FI
YO Fellowship session Monday, 11 September 2017, 14:15-15:45 90 min
Title symposium Fellowships in Europe: Educational opportunities for Young
Oncologists
Chair Christoph Zielinski, AT
Co-Chair Valentina Guarneri, IT
Title presentation 1 Introduction
Speaker 1 Valentina Guarneri, IT
Lecture time 1 5’
Title presentation 2 Overview ESMO Fellowship Programme and Leaders Generation
Programme
Speaker 2 Christoph Zielinski, AT
Lecture time 2 15’
Title presentation 3 Practical tips from a former fellow
Speaker 3 Valentina Gambardella, ES
Lecture time 3 15’
Title presentation 4 Best fellowship project 1
Speaker 4 Petr Szturz, CZ
Lecture time 4 10’
Title presentation 5 Best fellowship project 2
Speaker 5 Vincenza Conteduca, IT
Lecture time 5 Best fellowship project 1
Title presentation 6 How my ESMO Fellowship impacted my career
Speaker 6 Leticia De Mattos-Arruda, UK
Lecture time 6 15’
Awards: Presentation of the 2017 fellows and Best Exam Award 2016
20’
YO Forum Monday, 11 September 2017, 16:00-17:30 90 min
Title symposium Management skills that help you organise your everyday life in
oncology
Chair Mila Petrova, BG
Co-Chair Radu Vidra, RO
Title presentation 1 How to benefit from opportunities in a competitive environment
Speaker 1 Erika Martinelli, IT
Session Shooter 1 Guillem Argiles Martinez, ES
Lecture time 1 20’ with questions
Title presentation 2 Time management: Handling priorities and necessities
Speaker 2 Evandro De Azambuja, BE
Session Shooter 2 Claudia Cardone, IT
Lecture time 2 20’ with questions
Title presentation 3 Finding a mentor
Speaker 3 Rolf A. Stahel, CH
Session Shooter 3 Mehmed Akif Ozturk, TR
Lecture time 3 20’ with questions
Title presentation 4 Leadership: How to run a complex team
Speaker 4 Christoph Zielinski, AT
Session Shooter 4 Teresa Amaral, PT
Lecture time 4 20’ with questions
Discussion 10’
PAWG Friday, 8 September 2017, 14:00-14:30 30 mins
Title Welcome
Title presentation 1 ESMO
Speaker 1 Paolo Casali, IT
Title presentation 2 ESMO PAWG
Speaker 2 Bettina Ryll, SE
Title presentation 3 EACR
Speaker 3 Richard Marais, UK
Friday, 8 September 2017, 14:45-15:45 60 mins
Title Science by patients for patients
Chair Bettina Ryll, SE
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Science and advocacy: Why care about science? How to involve patients in research
Speaker 1 Jan Geissler, DE
Lecture time 15’
Title presentation 2 Involvement of patients in pathology
Speaker 2 Peter Smittenaar, UK
Lecture time 15’
Title presentation 3 The citizen scientist: Statistics for citizen
Speaker 3 Darren L. Dahly, IE
Lecture time 15’
Title presentation 4 Discussion
Lecture time 15’
Friday, 8 September 2017, 16:15-17:15 60 mins
Title Health services research in cancer
Chair Kathi Apostolidis, GR
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Health services research in Europe and its use for informing cancer policy
Speaker 1 Tit Albreht, SI
Lecture time 15’
Title presentation 2 Cancer patient experience from referral to hospital performance
Speaker 2 George Lyratzopoulos, UK
Lecture time 15’
Title presentation 3 What cancer patients want
Speaker 3 Karen Benn, IT
Lecture time 15’
Title presentation 4 The importance of healthcare systems research for improving health in CEE
Speaker 4 Vlad Voiculescu, RO
Lecture time 10’
Title presentation 5 Discussion
Lecture time 5’
Friday, 8 September 2017, 17:30-19:00 90 mins
Title Debate: Transparency in working with industry
Chair Jan Geissler, DE
Co-Chair David Herry, BE
Title presentation 1 Introduction
Speaker 1 Jan Geissler, DE
Lecture time 10’
Title presentation 2 A medical society’s perspective on disclosure and conflict of interest
Speaker 2 ESMO: Paolo G. Casali, IT Lecture time 10’
Title presentation 3 Does industry collaboration with clinicians and patient advocates compromise their objectivity?
Speaker 3 EFPIA: Nathalie Moll, BE
Lecture time 10’
Title presentation 4 The impartial patient voice when advising regulators and industry
Speaker 4 EATG: David Herry, BE
Lecture time 10’
Title presentation 5 A regulatory perspective on disclosure of interests of clinicians, patient experts and their organisations.
Speaker 5 EMA: Juan Garcia-Burgos, UK
Lecture time 10’
Title presentation 6 The media perspective on disclosure and conflict of interests
Speaker 6 Anna Wagstaff, UK
Lecture time 10’
Title presentation 7 Moderated panel discussion
Lecture time 30’
Saturday, 9 September 2017, 12:00-14:30 (Lunch 14:.00-14:30) 90 mins
Title Management of immuno-oncology side effects
Chair Ana-Maria Forsea, RO
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Immuno-oncology: Overview of existing therapies and what is coming next?
Speaker 1 John Haanen, NL
Lecture time 15’
Title presentation 2 Predicting response to immune therapies
Speaker 2 Thomas Gajewski, US
Lecture time 15’
Title presentation 3 Managing side effects on Immune therapies
Speaker 3 Paolo Ascierto, IT
Lecture time 15’
Title presentation 4 The patient’s advocate perspective Speaker 4 Gilliosa Spurrier, FR
Lecture time 15’
Title presentation 4 Discussion
Lecture time 30’
Saturday, 9 September 2017, 18:00-19:30 90 mins
Title Bio-ethical controversies and what they mean to research and European inequalities
Chair Ananda Plate, BE
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 The regulatory perspective
Speaker 1 Kari Steig, NO
Lecture time 15’
Title presentation 2 The academic perspective
Speaker 2 Itziar de Leucona, ES
Lecture time 15’
Title presentation 3 The clinical researcher perspective
Speaker 3 To be announced
Lecture time 15’
Title presentation 3 The patient perspective (incl. fertility)
Speaker 3 Louise Bayne, UK
Lecture time 15’
Title presentation 4 Discussion
Lecture time 30’
Sunday, 10 September 2017, 12:00-14:30 (Lunch 14:.00-14:30)
90 mins
Title What is it a good outcome?
Chair Ian Banks, UK
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 How to integrate qualitative research into clinical trials
Speaker 1 Annemarie Nelson, UK
Lecture time 15’
Title presentation 2 What are meaningful patient outcomes and how to implement them
Speaker 2 Ebba Carbonnier, SE
Lecture time 15’
Title presentation 3 Risk benefit assessment tool
Speaker 3 Bettina Ryll, SE
Lecture time 15’
Title presentation 3 Measuring Quality of Life - and deltas of perceptions between HCPs and patients
Speaker 3 Fabio Efficace, IT
Lecture time 15’
Title presentation 4 Discussion
Lecture time 30’
Sunday, 10 September 2017, 18:00-19:30 90 mins
Title Rare cancers: More common than you think, more difficult to serve
Chair Kathy Oliver, UK
Co-Chair Jean-Yves Blay, FR
Title presentation 1 The EURORDIS table: Similarities and differences of rare cancers and rare diseases
Speaker 1 Kathy Oliver, UK
Lecture time 15’
Title presentation 2 Joint actions on rare cancers
Speaker 2 Paolo Casali, IT
Lecture time 15’
Title presentation 3 What EUROCAN, the European Reference Network for Rare Cancers, will do for patients
Speaker 3 Jean-Yves Blay, FR
Lecture time 15’
Title presentation 3 The importance of adaptive pathways in rare cancers
Speaker 3 Francesco Pignatti, UK
Lecture time 15’
Title presentation 4 Discussion
Lecture time 30’
Monday, 11 September 2017, 13:00-14:30 (Lunch 12:30-13:00)
Title The Hans Keulen Memorial Debate Topic: Lost in rehabilitation
Chair Kathy Oliver, UK
Co-Chair Francoise Meunier, BE
Title presentation 1 Moderated discussion
Speaker 1 Special guests: Isabelle Lebroquy, FR Roger Henriksson, SE Luzia Travado, PT Steve Boorman, UK